LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Akcijų sąrašas・Merck & Co Inc.

Merck & Co Inc.

Uždarymo kaina

SektoriusSveikatos priežiūra

112.58 1.16

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

110.97

Max

112.86

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.2B -4.2B
Pardavimai	-114M 16B
P/E Sektoriaus vid.	31.347 51.415
Pelnas, tenkantis vienai akcijai	-1.28
Dividendų pajamingumas	2.94
Pelno marža	-26.053
Darbuotojai	73,000
EBITDA	-6.2B -1.9B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+21.75% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.94% 2.34%
Kitas uždarbis	2026-08-04
Kitas dividendų mokėjimo data	2026-07-07
Kita Ex Dividend data	2026-06-15

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.6B 275B
Ankstesnė atidarymo kaina	111.42
Ankstesnė uždarymo kaina	112.58

Naujienos nuotaikos

By Acuity

54%

46%

249 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

76.03 / 83.28 Palaikymas ir pasipriešinimas

Merck & Co Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 14:20; UTC

Uždarbis

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

2026-04-30 10:45; UTC

Uždarbis

Merck 1Q Sales Rise on Continued Keytruda Growth

2026-05-05 18:12; UTC

Uždarbis

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-05-05 13:54; UTC

Uždarbis

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-05-05 12:48; UTC

Įsigijimai, susijungimai, perėmimai

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

2026-05-05 12:48; UTC

Įsigijimai, susijungimai, perėmimai

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

2026-05-05 12:47; UTC

Įsigijimai, susijungimai, perėmimai

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

2026-05-05 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 14:53; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-04-30 13:27; UTC

Uždarbis

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

2026-04-30 10:47; UTC

Uždarbis

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

2026-04-30 10:30; UTC

Uždarbis

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck 1Q Pharmaceutical Sales Up 5% >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck 1Q Animal Health Sales Up 13% >MRK

2026-04-30 10:30; UTC

Uždarbis

Merck 1Q Sales $16.29B >MRK

Akcijų palyginimas

Kainos pokytis

Merck & Co Inc. Prognozė

Kainos tikslas

By TipRanks

21.75% į viršų

12 mėnesių prognozė

Vidutinis 135.61 USD 21.75%

Aukščiausias 179 USD

Žemiausias 112 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Merck & Co Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Merck & Co Inc. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

76.03 / 83.28Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

249 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.